Reality check for credit as omicron research timeline extends
Another dose of harsh reality has sunk into financial markets on Tuesday, as investors continue to reappraise the impact of tightening travel restrictions and the timeline for pharmaceutical work to address the omicron covid-19 variant
Subscriber-only article
This article is available only to Creditflux subscribers and free trial users within 30 days of publication.
Already a subscriber? Not logged in? Click here to login.
If you have not already done so,
you may request a FREE TRIAL by clicking here
This trial will give you:
- 4-weeks' free online access to our
most recent subscriber-only articles - Daily breaking news alert sent by email
- A print copy of Creditflux
If you currently have a free trial, you will see this message when you try to view articles older than 30 days.
Related Stories
- Nassau joins delayed draw issuance wave 18 hours ago
- Another 2015 vintage US CLO gets refi 20 hours ago
- CSAM prices third new US CLO of the year 21 hours ago
- Blackstone chooses static structure for new European CLO 21 hours ago
- KKR prices its first new US CLO of 2024 22 hours ago
Funds
- Global Loan Highlights 1Q24: Don’t call it a comeback 23 hours ago
- Houlihan Lokey adds new credit MD 1 day ago
- Swedish credit specialist closes European lending fund with EUR 1.7bn 1 day ago
- Pemberton raises EUR 2.3bn for opportunistic direct lending fund 1 day ago
- South Carolina pension system commits USD 100m to asset backed fund 1 day ago